article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound


That’s the part of the process that’s analgous to the library evolution phase of Galaxy The classical approach beloved of large pharma companies is really a brute-force method: make as many molecules as you can to assemble the SAR.

article thumbnail

Women in Stem with Dr Mrunal Jaywant

Drug Target Review

After working for pharma companies for nearly 20 years, I decided to work with USP so that I could utilise my skills in the development of standards. At USP India, Dr Jaywant oversees the Compendial Development, the Synthetic Chemistry, and the Analytical Research and Development Laboratories.